In the report, Greider analyzed that in at least nine pharmaceutical companies, who sell to American senior, spent more than twice the money on marketing advertising than on r&d (research and development). In other words, although pharmaceutical companies invest in research and development, there are situations where funding are not completely invested to actually further research but in other areas, such as marketing. Although it is important to advertise the treatments, there shouldn’t major contributions in marketing since that money can be more efficient to further developing drugs. Furthermore, the the article Rising Prescription Drug Costs Point to Drug Pricing Reform, further describes the escalation of prices and consumers. For example, James D. Chambers, describes it as a paradox, since we want to develop more treatments however, we cannot afford them and that drug prices can be reduced by collaborating with hospital and physicians, just like the company Blue Shield ( Harris Samantha 1). In other words, we want to continue to research and develop treatments, yet we cannot afford them because the prices are too high. Also, there are methods to reduce the prices of treatments so that people can afford them,